Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$4.73
+0.01 (+0.21%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $21.6M · quality 40.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.6B
P/E
N/A
•EV/EBITDA
41.8x
↑ROE
-3.3%
↓Gross Margin
47.4%
↓Debt/Equity
0.39
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-4.9%
FCF CAGR
+12.9%
FCF margin
20.5%
FCF / Net income
-5.97x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.05B · net income $-104.4M · FCF $623.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.05B | $3.05B | $3.83B | $4.26B | $3.54B |
| Net Income | $-104.4M | $-104.4M | $33.6M | $-414.5M | $138.5M |
| EBITDA | $168.4M | $168.4M | $269.6M | $-283.7M | $376.9M |
| EPS | -0.08 | -0.08 | 0.02 | -0.30 | 0.10 |
| Gross Margin | 47.4% | 47.4% | 58.1% | 55.3% | 60.1% |
| Operating Margin | 7.5% | 7.5% | 3.2% | -6.1% | 9.1% |
| Net Margin | -3.4% | -3.4% | 0.9% | -9.7% | 3.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.39 | 0.39 | 0.56 | 0.52 | 0.39 |
| Current Ratio | 0.95 | 0.95 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $623.5M | $623.5M | $-33.0M | $21.6M | $433.7M |
| Returns | |||||
| ROE | -3.3% | -3.3% | 1.1% | -12.7% | 3.5% |
| Valuation | |||||
| P/E | — | — | 190.50 | — | 80.70 |
| EV/EBITDA | 41.83 | 41.83 | 28.96 | — | 32.22 |
| P/B | 1.96 | 1.96 | 2.01 | 3.34 | 2.80 |
| Growth & Yield | |||||
| Revenue Growth | -20.3% | -20.3% | -10.3% | 20.4% | — |
| EPS Growth | -500.0% | -500.0% | 106.7% | -400.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+16.2%
Start / end P/E
n/dx → n/dx
EPS bridge
0.02 → -0.08
Residual
+16.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.